ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

ClinicalTrials.gov ID: NCT02952508

Public ClinicalTrials.gov record NCT02952508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)

Study identification

NCT ID
NCT02952508
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Enrollment
120 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 25, 2017
Primary completion
Jun 21, 2026
Completion
Dec 21, 2027
Last update posted
Mar 17, 2026

2017 – 2027

United States locations

U.S. sites
29
U.S. states
18
U.S. cities
28
Facility City State ZIP Site status
Cellectar Biosciences site Los Angeles California 90095
Cellectar Biosciences site Redlands California 92373
Cellectar Biosciences site Washington D.C. District of Columbia 20007
Cellectar Biosciences site Jacksonville Florida 32224
Cellectar Biosciences site Miami Florida 33165
Cellectar Biosciences site Tampa Florida 33612
Cellectar Biosciences Atlanta Georgia 30332
Cellectar Biosciences site Maywood Illinois 60153
Cellectar Biosciences site Warrenville Illinois 60555
Cellectar Biosciences site Westwood Kansas 66205
Cellectar Biosciences site New Orleans Louisiana 70121
Cellectar Biosciences site Baltimore Maryland 21287
Cellectar Biosciences Bethesda Maryland 20817
Cellectar Biosciences site Boston Massachusetts 02215
Cellectar Biosciences North Bergen New Jersey 07047
Cellectar Biosciences site Buffalo New York 14263
Cellectar Biosciences site New York New York 10065
Cellectar Biosciences site Rochester New York 14642
Cellectar Biosciences site Durham North Carolina 27705
Cellectar Biosciences Canton Ohio 44718
Cellectar Biosciences site Cincinnati Ohio 45219
Cellectar Biosciences Site Charleston South Carolina 29425
Cellectar Biosciences Greenville South Carolina 29605
Cellectar Biosciences site Knoxville Tennessee 37920
Cellectar Biosciences site Dallas Texas 75246
Cellectar Biosciences site Dallas Texas 75390
Cellectar Biosciences site Houston Texas 77030
Cellectar Biosciences site Seattle Washington 98109
Cellectar Biosciences site Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02952508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 17, 2026 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02952508 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →